Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 21× · first seen 09-sep-2026 · last seen 13-nov-2026

SGLT2 Inhibitors

Current understanding

To be populated as evidence accumulates.

Evidence log

Open questions

Related

Contributing findings

pubmed trial early human-rct
Effects of henagliflozin proline tablets versus metformin extended-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (HABIT-GEMs): study protocol for a multicentre, randomised, open-label trial.
11-nov-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.
02-nov-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.
01-nov-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.
26-oct-2026 novelty 3 per-area 3 strengthens
pubmed observational
Association between SGLT2 inhibitor use and functional outcomes in elderly patients receiving ferric carboxymaltose: a retrospective observational cohort study.
21-oct-2026 novelty 2 per-area 2 strengthens
pubmed review
Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework.
17-oct-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.
09-oct-2026 novelty 3 per-area 3 strengthens
pubmed preclinical animal-model
Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions.
06-oct-2026 novelty 3 per-area 3 strengthens
pubmed review
Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.
30-sep-2026 novelty 2 per-area 1 mentions
pubmed observational
Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial.
29-sep-2026 novelty 2 per-area 2 mentions
pubmed observational human-observational
Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.
27-sep-2026 novelty 3 per-area 3 strengthens
pubmed review
Trajectory-Oriented Brain Vulnerability Framework for Cognitive Decline in Type 2 Diabetes.
19-sep-2026 novelty 2 per-area 2 mentions
pubmed review
Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.
19-sep-2026 novelty 2 per-area 2 strengthens
pubmed observational
The Effect of Glucagon-Like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter-2 Inhibitors Alone and in Combination on AF Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation.
17-sep-2026 novelty 2 per-area 2 strengthens
pubmed observational human-observational
Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m: A Target Trial Emulation.
25-aug-2026 novelty 3 per-area 3 strengthens
pubmed review
The dual role of the cGAS-STING signaling pathway in kidney diseases: from acute injury to chronic fibrosis - molecular mechanisms and precision therapeutic strategies.
05-aug-2026 novelty 2 per-area 2 mentions
pubmed review expert-opinion
Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies.
01-aug-2026 novelty 3 per-area 3 strengthens
pubmed other mechanism-plausible
A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.
01-aug-2026 novelty 3 per-area 3 strengthens
pubmed review
Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways.
16-jul-2026 novelty 2 per-area 3 strengthens
pubmed observational
Divergent Risks of Endocrine and Nonendocrine Malignancies in GLP-1 Receptor Agonist Users: A Propensity-Matched Real-World Analysis of Over 140 000 Patients.
15-may-2026 novelty 3 per-area 1 mentions
pubmed trial late human-rct
Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial.
07-mar-2026 novelty 3 per-area 3 strengthens

build build 880 · 2bcef25 · 2026-11-18